Oct 04, 2021
LivaNova to Host Conference Call for Third Quarter 2021 Results
LONDON --(BUSINESS WIRE)--Oct. 4, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third quarter 2021 results on Wednesday, November 3, 2021 at 12 p.m.   London time ( 8 a.m. Eastern Daylight Time ).
Aug 26, 2021
LivaNova to Present at the Baird 2021 Global Healthcare Conference
LONDON --(BUSINESS WIRE)--Aug. 26, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present at the Baird 2021 Global Healthcare Conference on Wednesday, September 15 at 9:40 a.m.
Aug 16, 2021
LivaNova Announces Early Retirement of $450 Million Term Loan and Executes $125 Million Revolving Credit Facility
Announcement follows closing of underwritten offering of ordinary shares LONDON --(BUSINESS WIRE)--Aug. 16, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the early retirement of its $450 million five-year senior secured term loan (the
Aug 03, 2021
LivaNova Prices Offering of Ordinary Shares
LONDON --(BUSINESS WIRE)--Aug. 3, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that it has priced an underwritten offering of 3,636,364 ordinary shares at a price to the public of $82.50 per share.
Aug 02, 2021
LivaNova Announces Offering of Ordinary Shares
LONDON --(BUSINESS WIRE)--Aug. 2, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has commenced an underwritten offering of $300 million of its ordinary shares. LivaNova also intends to grant the underwriters of the offering a 30-day
Jul 28, 2021
LivaNova Reports Second Quarter 2021 Results and Appoints Alex Shvartsburg as Chief Financial Officer
LONDON --(BUSINESS WIRE)--Jul. 28, 2021-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2021 . For the second quarter of 2021, worldwide sales from continuing operations were $264.5 million , an
Jun 28, 2021
LivaNova to Host Conference Call for Second Quarter 2021 Results
LONDON --(BUSINESS WIRE)--Jun. 28, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2021 results on Wednesday, July 28, 2021 at 1 p.m.   London time ( 8 a.m. Eastern Daylight Time ).
Jun 15, 2021
LivaNova Receives FDA Approval for Clinical Study to Evaluate the aura6000 System to Treat Obstructive Sleep Apnea
Company to launch OSPREY investigational device exemption clinical study in the U.S. LONDON --(BUSINESS WIRE)--Jun. 15, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has received approval from the U.S.
Jun 01, 2021
LivaNova Completes Initial Closing of Heart Valve Business to Gyrus Capital
Additional local business closings to occur later this year LONDON --(BUSINESS WIRE)--Jun. 1, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has successfully completed the initial closing of the divestiture of its heart valve (HV)
May 13, 2021
LivaNova to Present at the UBS Global Healthcare Virtual Conference
LONDON --(BUSINESS WIRE)--May 13, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 8 a.m. Eastern Time .
Apr 28, 2021
LivaNova Reports First Quarter 2021 Results
LONDON --(BUSINESS WIRE)--Apr. 28, 2021-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021 . For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million , an
Apr 26, 2021
LivaNova and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression
LONDON --(BUSINESS WIRE)--Apr. 26, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Verily, a subsidiary of Alphabet focused on life sciences and healthcare, today announced that the first patient has been enrolled in their collaborative UNCOVER
Apr 20, 2021
LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine
Intuitive, optical-based technology system now available around the world LONDON --(BUSINESS WIRE)--Apr. 20, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for
Apr 19, 2021
LivaNova Achieves Clinical Milestone in Heart Failure Program
300th patient randomized in ANTHEM-HFrEF pivotal study LONDON --(BUSINESS WIRE)--Apr. 19, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the A uto n omic Regulation Th erapy to E nhance M
Mar 25, 2021
LivaNova to Host Conference Call for First Quarter 2021 Results
LONDON --(BUSINESS WIRE)--Mar. 25, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2021 results on Wednesday, April 28, 2021 at 12 p.m.   London time ( 7 a.m. Eastern Daylight Time ).
Feb 24, 2021
LivaNova Reports Fourth Quarter and Full-Year 2020 Results
LONDON --(BUSINESS WIRE)--Feb. 24, 2021-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020 . For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6
Jan 20, 2021
LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2020 Results
LONDON --(BUSINESS WIRE)--Jan. 20, 2021-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2020 results on Wednesday, February 24, 2021 at 1 p.m.   London time ( 8 a.m.